
A salesman's instinct for people brought Jim Robinson to the edge of cell therapy. At A2 Bio, his job is to turn a biological logic gate into an organization that can deliver on it.

He learned the rules inside global pharma, then chose companies where every arrival matters. At Deep Genomics, Brian O’Callaghan’s job is to turn formidable RNA research into a business that can deliver medicines.

Across 26 years at Lilly and seven as Neurocrine's chief medical officer, Eiry Roberts learned that drug development is less a straight line than a chain of judgment calls. Her next chapter puts that operating memory to work in the boardroom.